Finally, in a meta-analysis of randomized controlled trials, SGLT-2 decreased albuminuria, slowing the progression of microalbuminuria to macroalbuminuria and reducing the risk of end-stage renal disease [41]. The gene discussed is SLC5A2; the disease is stage 5 chronic kidney disease.